Media headlines about FibroGen (NASDAQ:FGEN) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. FibroGen earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.5128443304869 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- FibroGen, Inc (FGEN) Director Sells $93,300.00 in Stock (americanbankingnews.com)
- ETFs with exposure to FibroGen, Inc. : November 20, 2017 (finance.yahoo.com)
- FibroGen Sees Unusually Large Options Volume (FGEN) (americanbankingnews.com)
- Thomas F. Kearns, Jr. Sells 18,000 Shares of FibroGen, Inc (FGEN) Stock (americanbankingnews.com)
- Notable Stocks in Focus: Crocs, Inc., (NASDAQ: CROX), FibroGen, Inc., (NASDAQ: FGEN), Pretium Resources Inc … – Stocks In The News (press release) (tradingnewsnow.com)
FGEN has been the subject of several research analyst reports. Stifel Nicolaus restated a “buy” rating and issued a $80.00 price objective on shares of FibroGen in a research note on Thursday, September 14th. Jefferies Group LLC restated a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a research note on Tuesday, September 12th. BidaskClub downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Mizuho restated a “hold” rating and issued a $61.00 price objective on shares of FibroGen in a research note on Thursday, November 9th. Finally, William Blair restated an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. FibroGen has an average rating of “Buy” and a consensus price target of $65.67.
FibroGen (FGEN) traded up $0.25 during midday trading on Tuesday, reaching $47.80. 314,805 shares of the company’s stock traded hands, compared to its average volume of 628,263. FibroGen has a one year low of $19.25 and a one year high of $60.15. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83.
In related news, Director Kalevi Kurkijarvi sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $52.24, for a total value of $104,480.00. Following the completion of the sale, the director now owns 26,000 shares in the company, valued at $1,358,240. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Thomas B. Neff sold 38,636 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $43.73, for a total transaction of $1,689,552.28. Following the completion of the sale, the chief executive officer now owns 3,330,780 shares of the company’s stock, valued at approximately $145,655,009.40. The disclosure for this sale can be found here. Insiders have sold 457,518 shares of company stock valued at $23,754,691 in the last quarter. Insiders own 14.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact FibroGen (FGEN) Share Price” was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.truebluetribune.com/2017/11/21/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-fibrogen-fgen-share-price.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.